Noxopharm (ASX:NOX) has reached a significant milestone in its first-in-human trial of SOF-SKN, announcing that the initial multiple-dose cohort in the HERACLES study has been completed with no safety concerns identified. …
Noxopharm advances autoimmune candidate as first multiple-dose cohort clears safety review
December 3, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News -
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - - Latest News -
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - - Latest News -
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech